Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.71 |
| ▸ | LCK | P06239 | 4/20 | 0.57 |
| ▸ | RAF1 | P04049 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | FYN | P06241 | 3/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 3/20 | 0.56 |
| ▸ | FLT1 | P17948 | 3/20 | 0.56 |
| ▸ | FLT4 | P35916 | 3/20 | 0.56 |
| ▸ | TEK | Q02763 | 2/20 | 0.56 |
| ▸ | STK25 | O00506 | 1/20 | 0.56 |
| ▸ | CIT | O14578 | 1/20 | 0.56 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | PAK3 | O75914 | 1/20 | 0.56 |
| ▸ | STK10 | O94804 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1435177 | 0.91 | BRAF (0.69) | BRAFCYP3A4LCKRAF1KDR | |
| SCHEMBL1435192 | 0.87 | BRAF (0.72) | BRAFCYP3A4LCKRAF1KDR | |
| SCHEMBL2947319 | 0.87 | BRAF (0.79) | BRAFCYP3A4LCKRAF1KDR | |
| SCHEMBL1435217 | 0.87 | BRAF (0.71) | BRAFCYP3A4LCKRAF1KDR | |
| SCHEMBL1436443 | 0.85 | BRAF (0.67) | BRAFCYP3A4LCKRAF1KDR | |
| SCHEMBL1435592 | 0.84 | BRAF (0.78) | BRAFCYP3A4LCKRAF1KDR | |
| SCHEMBL2894143 | 0.83 | BRAF (0.76) | BRAFCYP3A4LCKRAF1KDR | |
| SCHEMBL1434920 | 0.83 | BRAF (0.58) | BRAFCYP3A4LCKRAF1KDR | |
| SCHEMBL1435438 | 0.83 | BRAF (1.00) | BRAFCYP3A4LCKRAF1KDR | |
| SCHEMBL1435105 | 0.83 | BRAF (1.00) | BRAFCYP3A4LCKRAF1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023956-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | Novartis AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007131689-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | NOVARTIS AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | BRAF, DSTYK, CHEK2 | BRAF 1/4885CYP3A4 1957/4885LCK 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.